Protembis, an Aachen, Germany-based cardiovascular medical device company, raised €30M in Series B funding.
The round was led by Segulah Medical Acceleration, XGEN Venture, and TechVision Fund. Other investors included Coparion, family offices, angel investors and a multinational medical device strategic.
The company intends to use the funds to support the enrollment of the ProtEmbo Investigational Device Exemption (IDE) Pivotal Trial (NCT05873816).
Led by CEOs Karl von Mangoldt and Conrad Rasmus, Protembis is a medical device company that has developed the ProtEmbo® Cerebral Protection System, which aims to become a solution to protect patients from brain injury during left-sided heart procedures, improving patient quality of life and reducing overall healthcare costs associated with brain injury during such procedures.
The ProtEmbo System is currently undergoing clinical investigations.
FinSMEs
26/03/2024